Radnostix, Inc. (INIS) Fair Value 2026

INIS · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-08-27, Radnostix, Inc. (INIS) trades at $0.06. QOC: 6.1/10. Value Trap Risk: 24/100 (SAFE). 0/13 models active.

Key Facts

Ticker
INIS
Price
$0.06
Quality Score
6.1/10
Value Trap Risk
24/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give INIS?

0 Intrinsic Value Models vs. Current Price ($0.06)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Radnostix, Inc. (INIS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Radnostix, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About INIS?

0 of 13 models are currently active for INIS. See which stocks rank higher →

How Does INIS Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, INIS ranks #54 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a healthcare company, Radnostix, Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating INIS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is INIS a Value Trap?

CirclFi's Value Trap algorithm assigns INIS a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Radnostix, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Radnostix, Inc.'s fundamental quality profile registers 6.1/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INIS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Radnostix, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

SBFMSunshine Biopharma, Inc.QOC 6.1AAWHAscend Wellness Holdings, Inc.QOC 6.1INCRInterCure Ltd.QOC 6.1OGIOrganigram Global Inc.QOC 6.1AYTUAytu BioPharma, Inc.QOC 6.1VTRSViatris Inc.QOC 6.0RGCRegencell Bioscience Holdings LimitedQOC 4.8SXTCChina SXT Pharmaceuticals, Inc.QOC 1.4ELANElanco Animal Health IncorporatedQOC 7.2UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: SBFM · AAWH · INCR · OGI · AYTU · VTRS · RGC · SXTC · ELAN · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to INIS?

7 companies across all industries closest to INIS’s Quality of Company score of 6.1/10.

FSKFS KKR Capital Corp.QOC 6.1OGCOceanaGold CorporationQOC 6.1TEOTelecom Argentina S.A.QOC 6.1JFBJFB Construction HoldingsQOC 6.1BXBLBoxabl Inc.QOC 6.1FFFutureFuel Corp.QOC 6.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FSK · OGC · TEO · JFB · BXBL · FF · NVDA

Where Does INIS Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

INIS is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Radnostix, Inc.’s Valuation?

What is Radnostix, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Radnostix, Inc. (INIS). The Quality of Company score is 6.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INIS overvalued or undervalued right now?

At $0.06, 0 of 0 active models suggest INIS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Radnostix, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 6.1 mean for INIS?

Radnostix, Inc.'s QOC of 6.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on INIS?

CirclFi analyzes INIS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is INIS a value trap in 2026?

Radnostix, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Radnostix, Inc. (INIS) a Quality of Company score of 6.1/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/INIS/ · Methodology
Primary sources for this INIS valuation
  • Financial statements: Radnostix, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001038277) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INIS as of ; valuations recomputed .